NASDAQ:ADIL Adial Pharmaceuticals Q3 2025 Earnings Results & Report $3.14 +0.14 (+4.67%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$3.14 +0.00 (+0.13%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Adial Pharmaceuticals beat analyst earnings expectations in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$2.00 versus the -$2.25 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 13, 2025TimeBefore Market OpensConference Call7:00 AM ET Adial Pharmaceuticals EPS ResultsActual EPS-$2.00Consensus EPS -$2.25Beat/MissBeat by +$0.25One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAdial Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAdial Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Adial Pharmaceuticals Q3 2025 Earnings FAQ Did Adial Pharmaceuticals beat earnings estimates for Q3 2025? Adial Pharmaceuticals (NASDAQ:ADIL) reported earnings of -$2.00 per share for Q3 2025, beating the consensus estimate of -$2.25. The report was announced on Thursday, November 13, 2025. When is Adial Pharmaceuticals' next earnings date? Adial Pharmaceuticals' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Adial Pharmaceuticals on the company's earnings history page. Adial Pharmaceuticals Earnings HeadlinesAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)September 30, 2026 | globenewswire.comAdial Pharmaceuticals Announces Board AppointmentsSeptember 18, 2026 | marketscreener.comMBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing December 8th. | Paradigm Press (Ad)Adial Shareholders Approve Key Proposals, Meeting AdjournedSeptember 18, 2026 | tipranks.comAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)August 25, 2026 | globenewswire.comAdial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business UpdateAugust 17, 2026 | globenewswire.comSee More Adial Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email. Email Address About Adial PharmaceuticalsAdial Pharmaceuticals (NASDAQ:ADIL) (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. The company uses a genetically targeted approach intended to identify patients who may be more likely to respond to specific therapies. Adial’s lead product candidate, AD04, is an investigational formulation of ondansetron, a selective serotonin-3 receptor antagonist. It is being developed for the treatment of alcohol use disorder, with the goal of reducing alcohol consumption and supporting abstinence in genetically selected patient populations. The company has also evaluated the potential application of its platform in other addictive disorders, including smoking cessation. Founded in 2011, Adial Pharmaceuticals is headquartered in Charlottesville, Virginia. Its development programs are subject to clinical testing and regulatory review, and the company’s therapies are not approved for commercial use unless and until applicable regulatory requirements are satisfied. William M. Stilley has served as the company’s chief executive officer.View Adial Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
